Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Spot the adenoma after pituitary apoplexy following a SARS-CoV-2 vaccination

Josef Finsterer, Fulvio A. Scorza, Antonio-Carlos G. de Almeida

Neurology & Neurophysiology Center, Vienna, Austria
Disciplina de Neurociência, Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM), São Paulo, Brazil
Centro de Neurociências e Saúde da Mulher “Professor Geraldo Rodrigues de Lima”, Escola Paulista de Medicina/Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, Brazil

A R T I C L E  I N F O
Article history:
Received 1 October 2022
Accepted 12 October 2022
Available online xxxx

Keywords:
SARS-CoV-2
COVID-19
Side effect
Vaccination
Headache
Hemianopia

A B S T R A C T
Pituitary apoplexy often manifests with a severe headache and is often caused by bleeding in a pituitary adenoma, which is common and often undiagnosed. The pituitary gland is damaged when the tumour suddenly enlarges due to bleeding. Bleeding into the pituitary can block blood supply to the pituitary gland. The larger the tumour, the higher the risk of a future pituitary apoplexy. Since only few cases have been reported, the SARS-CoV-2 vaccine is unlikely to cause pituitary apoplexy. Patients with new-type headache require neurological evaluation and may require cerebral imaging to rule out bleeding, ischaemia, venous sinus thrombosis, meningitis, encephalitis, pituitary apoplexy, reversible cerebral vasocostriction syndrome, dissection, or migraine.

© 2022 International Hemorrhagic Stroke Association. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Letter to the editor

We read with interest the article by Roncati et al. about a 28 years-old female who developed previously unknown tension-type headache for one month after the first dose of the Vaxzevira vaccine, of which the cause was not identified.1 Two months after the first dose, she received the second dose and headache came back, but more intense than after the first dose and in association with amenorrhoea and hyperprolactinemia.1 Serial MRIs revealed pituitary apoplexy, that partially resolved after three months.1 The study is appealing but raises concerns that should be discussed.

Apoplexy is commonly associated with classical cardio-vascular risk factors for stroke or embolism. Therefore, we should know if the index patient had diabetes, arterial hypertension, hyperlipidaemia, or atrial fibrillation, even in the absence of a previously uneventful history. Furthermore, we should know if the patient was taking an anti-contraceptive pill or if she was a smoker. Providing this information is crucial as the combination of both or either of the two can promote thrombosis.

Because pituitary apoplexy after SARS-CoV-2 infection is commonly associated with pituitary adenoma,2 we should be told if the index patient had micro-adenoma or macro-adenoma of the pituitary gland as well. Knowing this information is crucial as it may determine the therapeutic regimen significantly. Pituitary apoplexy plus pituitary adenoma may require endoscopic trans-nasal resection. Pituitary apoplexy is usually caused by bleeding inside a pituitary adenoma, which is common and often undiagnosed. The pituitary gland is damaged when the tumour suddenly enlarges due to bleeding. It either bleeds into the pituitary or blocks blood supply to the pituitary. The larger the tumour, the higher the risk for future pituitary apoplexy.

Although pituitary apoplexy has been repeatedly reported in patients with SARS-CoV-2 infection,1 it has been only rarely reported as a complication of anti-SARS-CoV-2 vaccinations (Table 1).1,4–7 This circumstance could indicate that there is no causal relation between anti-SARS-CoV-2 vaccination and pituitary apoplexy or that pituitary apoplexy is truly an extremely rare side effect of the vaccination.

Although the patient was reported not complaining of visual disturbance,1 we should be informed if the patient underwent ophthalmologic investigations, particularly visual field examination, and if this investigation revealed heteronymous hemianopia to the left respectively right.

Missing is the information if the index patient was truly SARS-CoV-2 negative. Because pituitary apoplexy occurs much more commonly in association with a SARS-CoV-2 infection than...
a vaccination\(^2\) and because anti-SARS-CoV-2 vaccination does not rule a SARS-CoV-2 infection, it is crucial to know the results of the PCR test.

The index patient had previously unknown headache following the first dosage of Vaxzevira.\(^1\) Therefore, it cannot be ruled out that the patient had pituitary apoplexy already earlier, or that other causes were responsible for post-SARS-CoV-2 vaccination headache. The results of cerebral imaging after the first vaccine dose should be provided.

Overall, the interesting study has limitations that call the results and their interpretation into question. Addressing these limitations could further strengthen and reinforce the statement of the study. Patients with new type of headache require neurological exam and eventually cerebral imaging to rule out bleeding, ischemia, venous sinus thrombosis, meningitis, encephalitis, pituitary apoplexy, reversible cerebral vasoconstriction syndrome, dissection, or migraine.

Declarations

Funding sources: no funding was received.
Ethics approval: was in accordance with ethical guidelines. The study was approved by the institutional review board.
Consent to participate: was obtained from the patient.
Consent for publication: was obtained from the patient.
Availability of data: all data are available from the corresponding author.
Code availability: not applicable.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

None.

References

1. Roncati L, Manenti A. Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination. Brain Hemorrhages. 2022. https://doi.org/10.1016/j.brainhem.2022.04.002.
2. Liew SY, Seese R, Shames A, Majumdar K. Apoplexy in a previously undiagnosed pituitary macroadenoma in the setting of recent COVID-19 infection. BMJ Case Rep. 2021;14(7):ce243687.
3. Balmain J, Jarebi M, Al-Salameh A, et al. Pituitary apoplexy in the aftermath of a SARS-CoV-2 infection: a case series from Amiens University Hospital. Eur J Endocrinol. 2022;187(3):K19–K25. https://doi.org/10.1530/EJE-22-0056.
4. Zainordin NA, Hatta SFWM, Ab Mumin N, Shah FZM, Ghani RA. Pituitary apoplexy after COVID-19 vaccination: A case report. J Clin Transl Endocrinol Case Rep. 2022;22. https://doi.org/10.1016/j.jetcr.2022.100123.
5. Pifar-Gutiérrez A, Remón-Ruiz P, Soto-Moreno A. Case report: pituitary apoplexy after COVID-19 vaccination. Med Clin (Barc). 2022;158(10):498–499. https://doi.org/10.1016/j.medcli.2021.09.028.
6. Jaggi S. A rare endocrine complication of the COVID-19 vaccine. Endocrine Practice 2021;27:S116–S117.
7. Bin Yusof MF. Pituitary apoplexy following chadox1 ncov-19 (azd1222) vaccination: a potential culprit? Malaysian J Emerg Med. 2021;5.

Table 1

| Age | Gender | Vaccine brand | Dosage | LVO | MRI findings | Treatment | Outcome | Reference |
|-----|--------|---------------|--------|-----|--------------|-----------|---------|-----------|
| 24  | f      | AZV           | 2nd    | 1d  | apoplexy, adenoma | hydrocortisone | IR       | 4         |
| 37  | f      | Vaxzevira     | nr     | 5d  | apoplexy, adenoma | none      | CR      | 5         |
| 28  | f      | Vaxzevira     | 1st, 2nd | nr  | apoplexy      | none      | CR      | 1         |
| 44  | m      | nr            | 2nd    | 3d  | apoplexy, adenoma | resection | IR       | 6         |
| 24  | f      | Vaxzevira     | 2nd    | 6d  | apoplexy, adenoma | none      | nr      | 7         |

AZV: AstraZeneca vaccine, CR: complete recovery, IR: incomplete recovery, LVO: latency between vaccination and onset of clinical manifestations of pituitary apoplexy, nr: not reported.